1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

Slides:

Advertisements

Similar presentations

Insulin Therapy in Type 2 Diabetes: Current and Future Directions

Advertisements

Oral Hypoglycemic Drugs And Classifications

Pharmacotherapy Oral Hypoglycemic Agents (OHA) Antihyperglycemic agents Used only in type 2 diabetes, with diet and exercise CDA Clinical Practice Guidelines.

JARDIANCE: Newly Approved Drug to Lower HbA1C in Type-2 diabetes

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.

Pramlintide Acetate Safety Review Dragos Roman MD Center for Drug Evaluation and Research.

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

Farxiga™ - Dapagliflozin

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

Oral Medications to Treat Type 2 Diabetes

1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

HIV Drug Development in Neonates - What Now? Linda L. Lewis, M.D. Medical Officer Division of Antiviral Drug Products FDA.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

LONG TERM BENEFITS OF ORAL AGENTS

Afrezza® – inhaled human insulin

Yesterday, today, and tomorrow

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Orlistat Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

1 One Year Post Exclusivity Adverse Event Review: Alendronate Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP Medical.

Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.

1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.

Pediatric Advisory Committee April 11, Update to the Committee: Oxybutynin Central Anticholinergic Effects Pediatric Advisory Committee Meeting.

1 One Year Post-Exclusivity Adverse Event Review: Tolterodine Pediatric Advisory Committee Meeting June 29, 2005 Lawrence Grylack, MD Medical Officer Division.

DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENATIONS.

Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.

Drug Development —— Metformin. Diabetes type1 vs type2.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post-Exclusivity Adverse Event Review: Paricalcitol, Zolmitriptan, Dorzolamide, and Leflunomide Pediatric Advisory Committee Meeting June 29,

Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.

Toujeo® and it’s Place in Therapy

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

Orlistat 60 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees January 23, 2006 Andrea Leonard-Segal, M.D.

1 One Year Post Exclusivity Adverse Event Review: Esmolol Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer Division.

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

History of Pediatric Labeling

1 One Year Post-Exclusivity Adverse Event Review: Rosiglitazone Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Insulin Aspart Recombinant Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs,

1 One Year Post Exclusivity Adverse Event Review: Sibutramine Pediatric Advisory Committee Meeting March 22, 2006 Hari Cheryl Sachs, MD, FAAP Medical Officer.

Tresiba- insulin degludec

Food and Drug Administration Amendments Act of 2007 Reauthorization of Pediatric Initiatives Lisa L. Mathis, M.D. Pediatric and Maternal Health Staff Office.

Diabetes- Chapter 43 Revised 11/10. Types of Diabetes Type 1 — insulin- dependent diabetes mellitus (IDDM) Insulin produced in insufficient amount Requires.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.

Initiatives Drive Pediatric Drug Development January 30, 2002.

1 One Year Post Exclusivity Adverse Event Review: Venlafaxine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

1 Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting November 18, 2005 Solomon Iyasu, M.D., M.P.H. Acting.

1 One Year Post Exclusivity Adverse Event Review: Benazepril Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

Application of the 1998 Pediatric Rule to Oncology Steven Hirschfeld, MD PhD CDR U.S. Public Health Service Medical Officer Division of Oncology Drug Products.

Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Pediatric Advisory Committee: Overview of Role and Evolution of Process Dr. Dianne Murphy Director, Office of Pediatric Therapeutics, OC, FDA November.

1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.

Viagra (sildenafil citrate): Extensive Clinical and Post-Marketing Experience Michael Sweeney, MD Senior Medical Director Pfizer Inc.

Adlyxin® - Lixisenatide

Diabetes in the Pediatric Population

Dulaglutide Drugbank ID : DB09045.

Diabetes Journal Club Julie Shah.

Presentation transcript:

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical Officer Pediatric and Maternal Health Staff Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration

2 Background Drug Information Drug: Amaryl ® (glimepiride) Therapeutic Category: oral hypoglycemic agent Sponsor: Sanofi Aventis US Original Market Approval: November 30, 1995 Pediatric Exclusivity Granted: June 9, 2005 Related combination products: –Avandaryl™ (glimepiride and rosiglitazone, approved 11/05) –Duetact™ (glimepiride and pioglitazone, approved 7/06) Mechanism of action: stimulates insulin release from beta cells

3 Background Drug Information Indication: adjunct to diet and exercise to lower blood glucose in patients with type 2 diabetes mellitus –As monotherapy –Concomitantly with metformin or insulin Dosage: –Adults only: initial dose 1 to 2 mg daily with first main meal, maximum 8 mg maintenance

4 Glimepiride: Pediatric Exclusivity Labeling Changes Data are insufficient to recommend pediatric use Both pK and clinical trials for pediatric patients are described Single dose study (ages 10 to 17, n=30) 24 week clinical trial (n= 272, aged 8 to 17 years) Profile of adverse events similar to that in adults Comparative risk of hypoglycemia Hypoglycemia (BG < 36) observed in 4% of patients treated with glimepiride, 1% metformin

5 Glimepiride: Outpatient Use Total dispensed prescriptions for glimepiride and related antihyperglycemic agents (glipizide, glyburide, metformin and combinations of these) increased: –Overall: 8% from 73.6 to 79.4 million 1 (pre- and post- exclusivity; July 2004 to June 2005 vs. June 2005 to June 2006) –glimepiride: 7% from 6.7 to 7.2 million (same time period) 1 Amaryl (glimepiride) 4 th most commonly dispensed product 1 Pediatric use: < 1%, decreased from 5,890 to 4,210 (pre and post-exclusivity) 1 1 Verispan LLC, Vector One® National (VONA), Jul 2003 – Jun 2006, Data extracted Sep 2006

6 Glimepiride: Adverse Events Pediatric AEs < 1 % of total –Since Approval: 8/1494 –No pediatric deaths –During post-exclusivity period: 2/290 Two confounded, non-fatal, serious adverse events identified in pediatric patients during the post-exclusivity period: –17 year old with Trisomy 21 on amitryptiline who experienced behavioral abnormalities after 2 doses of glimepiride –Infant with congenital anomalies (VSD, microcephaly, dysmorphic facies) after in utero exposure to mother with history of multiple miscarriages and 2 children with congenital anomalies; consanguinity Labeling: Pregnancy category C; change to insulin. Not recommended for use in pregnancy

7 Summary: Glimepiride As a result of exclusivity studies, labeling indicates there are insufficient data to recommend pediatric use No new pediatric AEs identified during one-year post-exclusivity period This completes the one-year post-exclusivity adverse event reporting as mandated by BPCA The FDA recommends routine monitoring of glimepiride for AEs in all populations Does the Advisory Committee concur?

8 Acknowledgements OSE Laura Governale Lanh Green Joslyn Swann Rosemary Johann-Liang PMHS Lisa Mathis Kristin Phucas Jean Temeck DPEP Robert Misbin David Orloff OPT Dianne Murphy Ann Myers